Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells 1,704 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 1,704 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $27.56, for a total value of $46,962.24. Following the transaction, the chief executive officer owned 633,036 shares of the company’s stock, valued at $17,446,472.16. This trade represents a 0.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $27.02 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The company has a market capitalization of $1.63 billion, a PE ratio of -18.63 and a beta of 2.31. Twist Bioscience Corporation has a one year low of $24.07 and a one year high of $55.33. The business has a 50 day simple moving average of $28.90 and a 200 day simple moving average of $33.58.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TWST shares. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research report on Monday, August 4th. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $49.40.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Versant Capital Management Inc increased its stake in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at $58,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at $97,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.